This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endo Health Solutions' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Endo Health Solutions, Inc. (ENDP)

Q2 2012 Earnings Conference Call

August 07, 2012, 08:30 a.m. ET

Executives

Blaine Davis - SVP, Corporate Affairs

Dave Holveck - President and CEO

Julie McHugh - COO

Ivan Gergel - EVP, Research & Development and Chief Scientific Officer

Alan Levin - EVP and CFO

Analysts

Marc Goodman - UBS

Ken Cacciatore - Cowen and Company

Shibani Malhotra - RBC Capital Markets

Gregg Gilbert - Bank of America/Merrill Lynch

Corey Davis - Jefferies and Company

Annabel Samimy - Stifel Nicolaus

Trevor Davis - Piper Jaffray

Mike Faerm - Credit Suisse

Chris Schott - JP Morgan

Gary Nachman - Susquehanna Financial Group

Greg Waterman - Goldman Sachs

Presentation

Operator

Good day ladies and gentlemen, and welcome to Q2 2012 Endo Health Solutions Inc. Earnings Conference Call. My name is Sonia and I will be your operator for today. At this point, all participants are in listen-only mode. We will conduct the Q&A session towards the end of this conference call. (Operator Instructions) As a reminder this call is being recorded for replay purposes.

I’d like to turn the call over to Blaine Davis, Senior Vice President of Corporate Affairs. Please proceed.

Blaine Davis

Good morning. Thank you for joining us today. With me on this morning’s call are Dave Holveck, President and CEO of Endo; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer; and Alan Levin, Chief Financial Officer.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs